Neion Bio
18 employees on LinkedIn · 8 known investors
Neion Bio uses genetic engineering to turn chicken eggs into production systems for recombinant biologic proteins.
Also known as Neion · Neion Bio, Inc.
Investors · 8
Also in the syndicate · 1
Funding
SEC filings, press & company announcements$23M disclosed across 1 of 5 rounds · 2024–2026
- $23MSeries AJun 2026 · 3 sources
Caffeinated Capital (lead), Basis Set Ventures, Digitalis Ventures, Ensemble VC, Haystack, Trust Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Company profile
researched Aug 2026Neion Bio is a New York-based biotechnology company founded in 2024 that develops a biomanufacturing platform in which genetically engineered laying hens produce recombinant proteins inside their eggs. Its Raptor platform applies precision genome engineering to avian primordial germ cells: engineered PGCs carrying a targeted transgene are introduced into a prepared egg and, once incorporated into the germline, enable subsequent generations of hens to express specific recombinant proteins within the egg. The company describes the egg as a naturally sterile, non-invasively harvested vessel that already produces and stabilizes roughly six grams of complex protein, and states that its engineering replaces native egg proteins with target medical proteins while restricting expression to the egg itself.
The company positions the platform as an alternative to conventional mammalian (CHO) cell-culture manufacturing, claiming up to 10x lower cost of goods, up to 100x lower capital expenditure, low batch-to-batch variability, low scale-up risk and a 10-100x lower carbon footprint, with inputs limited to grain and water to support localized, onshore production. Molecule classes cited include monoclonal antibodies, multi-specifics, enzymes, cytokines, fusion proteins, peptides, therapeutic proteins and reagents, with an emphasis on complex, glycosylated and difficult-to-express proteins. Neion is also developing proprietary technologies intended to enable production of biologics at meaningful scale within days, shortening iteration cycles for screening novel molecules.
Neion emerged from stealth in March 2026 alongside its first commercial co-development and supply agreement, and closed a $23 million Series A in June 2026 to expand a pipeline spanning biosimilars, innovative medicines, critical reagents and animal health.
Founding story
Neion Bio was founded in 2024 by Demetrios (Dimi) Kellari and Dr. Sam Levin. Kellari, an MIT-trained aerospace engineer, previously worked as a technologist and investor at GoogleX, Cavnue, SIP, Airbus, CERN and McKinsey; Levin is an Oxford-trained evolutionary biologist whose doctorate addressed the origin of life and who previously built next-generation bioreactors at Melonfrost. The founding premise was that biological systems already optimized by evolution — specifically the egg, honed over roughly 200 million years and centuries of selective breeding — could be re-engineered into manufacturing systems for medicines instead of forcing biology into industrial equipment.
Business model
Neion Bio operates as an upstream biologics development and manufacturing partner, developing and producing biological molecules for third parties for therapeutic and non-therapeutic use rather than solely for its own account. Its first commercial agreement is a co-development and supply deal covering up to three monoclonal antibodies, structured with up-front payments, milestone payments and long-term profit sharing once products are commercialized, indicating a partnership model that combines near-term service and milestone revenue with downstream product economics. It also states an intent to build its own pipeline across biosimilars, innovative medicines, critical reagents and animal health.
Revenue sources disclosed to date consist of up-front payments, milestone-based payments and participation in commercial profits under co-development and supply agreements with pharmaceutical partners, plus manufacturing and supply of biological molecules at varying scales.
Traction
Neion emerged from stealth in March 2026 with its first co-development and supply agreement with a major global pharmaceutical company covering up to three monoclonal antibodies, including up-front and milestone payments and commercial profit participation. It closed an oversubscribed $23 million Series A in June 2026, following an approximately $11 million launch financing in 2024, and is expanding a pipeline across biosimilars, innovative medicines, critical reagents and animal health while recruiting for additional roles.
Latest developments
On June 11, 2026, Neion Bio announced the close of an oversubscribed $23 million Series A led by Caffeinated Capital, with new investors Digitalis Ventures, Ensemble VC and Trust Ventures and follow-on participation from Haystack and Basis Set Ventures. Proceeds are earmarked for pipeline expansion across biosimilars, innovative medicines, critical reagents and animal health, and for proprietary technologies intended to enable biologics production at meaningful scale within days.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Neion Bio competes in biologics manufacturing, a field dominated by CHO cell-culture-based contract development and manufacturing. Transgenic avian expression has precedent: Synageva BioPharma produced sebelipase alfa in eggs before its 2015 acquisition by Alexion, and one Neion advisor is described as a co-inventor of that original chicken-bioreactor drug. Neion's founders argue that recent progress in precision genome engineering makes the avian approach more tractable and scalable than earlier attempts. The company states an ambition to become a partner of choice for upstream biologics manufacturing and frames its localized production as relevant to domestic supply-chain security for critical medicines.
Differentiation rests on using the egg as the production vessel instead of steel bioreactors or disposable plastic systems, which the company links to substantially lower cost of goods and capital expenditure, minimal scale-up risk, low batch-to-batch variability, simpler purification, localizable inputs (grain and water) for onshore manufacturing, a lower carbon footprint, and the capacity to make complex glycosylated proteins that are difficult to produce by conventional methods.
Technology
The Raptor platform builds "living bioreactors" from engineered chickens using next-generation genome engineering and stem cell biology. Advances in precision genome editing, large genomic datasets and the ability to culture avian primordial germ cells make the approach possible: engineered PGCs carrying a targeted transgene are introduced into a prepared egg and incorporated into the germline so that later generations of hens express recombinant protein in the egg, with expression restricted to the egg. Public platform disclosures reference a "Raptor Line V2.5" and per-batch parameters such as genetic sequence ID, generation, batch ID, total protein mass (about 6,133 mg) and recombinant protein type (monoclonal antibody). The company states the egg's natural protein content and sterility allow simpler downstream purification, and highlights capability for complex, glycosylated proteins.
Go-to-market
Neion pursues direct commercial partnerships with biopharmaceutical companies, structured as co-development and supply agreements, and has hired a President of Commercial Operations, Ming Li, to build partnerships and commercial strategy across the biopharma ecosystem. Public visibility has been built through emergence from stealth in March 2026, a New York Times feature by Carl Zimmer, trade coverage, and funding announcements.
Biosimilar developers, biotech companies needing difficult-to-express proteins or long-term supply, animal health companies operating in cash-pay markets, and reagent suppliers. Its first disclosed customer is an undisclosed major global pharmaceutical company.
Geography
Headquartered in New York, United States; the company emphasizes localized, domestic (onshore) manufacturing and site flexibility, and targets biologic medicines for global markets.
History
The company launched in 2024 with approximately $11 million in financing from a consortium led by Caffeinated Capital with significant participation from Basis Set Ventures and Haystack VC. It recruited Dr. Sven Bocklandt, formerly of Colossal Biosciences, as Chief Scientific Officer, and appointed Ming Li, previously Chief Strategy Officer of Alvotech, as President of Commercial Operations. Neion emerged from stealth on March 26, 2026, simultaneously announcing its first multi-product biosimilar co-development and supply agreement and receiving coverage in The New York Times. In April 2026 it appointed James Kehler, VMD, PhD, previously Vice President of BioSynergy at Colossal Biosciences, as Head of Avian Sciences. On June 11, 2026 it announced an oversubscribed $23 million Series A.
Risks & controversies
Publicly disclosed performance claims — including up to 10x lower cost of goods, up to 100x lower capital expenditure and production at scale within days — are company statements rather than independently verified results. The approach also carries execution precedent risk: earlier transgenic avian manufacturing efforts, such as Synageva BioPharma's egg-produced sebelipase alfa, did not establish the platform as a mainstream alternative to CHO cell culture. The identity of the first pharmaceutical partner and the economics of that agreement have not been disclosed.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 6
launches, deals, and filingsNeion Bio announced an oversubscribed $23 million Series A led by existing investor Caffeinated Capital, with new investors Digitalis Ventures, Ensemble VC and Trust Ventures and follow-on investment from Haystack and Basis Set Ventures, to advance its Raptor platform and expand its pipeline across biosimilars, innovative medicines, critical reagents and animal health.
$23M source ↗
Neion Bio appointed James Kehler, VMD, PhD, previously Vice President of BioSynergy at Colossal Biosciences, as Head of Avian Sciences; his work cloning mammals from blood was named by TIME among the best inventions of 2025.
Industry veteran Ming Li, formerly Chief Strategy Officer of Alvotech, joined Neion Bio as President of Commercial Operations after previously serving as an advisor.
Neion Bio publicly launched its egg-based Raptor biologics manufacturing platform, disclosing approximately $11 million in prior financing, and was featured in The New York Times in an article by Carl Zimmer.
Alongside its emergence from stealth, Neion Bio signed its first commercial co-development and supply agreement with an undisclosed major global pharmaceutical company covering up to three monoclonal antibodies, with up-front payments, milestone payments and profit sharing upon commercialization.
The company launched in 2024 with approximately $11 million from a consortium of venture capital firms led by Caffeinated Capital, with significant participation from Basis Set Ventures and Haystack VC.
$11M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Neion Bioneionbio.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Neion Bio do?
- Neion Bio uses genetic engineering to turn chicken eggs into production systems for recombinant biologic proteins.
- Who are Neion Bio's investors?
- Neion Bio's investors include Caffeinated Capital, HAWKTAIL, Basis Set Ventures, Digitalis Ventures, Ensemble VC, Haystack, Trust Ventures.
- How much funding has Neion Bio raised?
- Neion Bio has disclosed $23M raised across 1 of its 5 known rounds.